Your browser doesn't support javascript.
loading
GPCR structure and function relationship: identification of a biased apelin receptor mutant.
Ban, Ting; Li, Xun; Ma, Xiaochuan; Yang, Hui; Song, Yunpeng; Sun, Yaping; Shen, Michelle; Li, Na; Zhang, Mei-Yun; Ma, Yingli; Zhong, Wenge; Zhang, Mingqiang; Hu, Liaoyuan A.
Afiliação
  • Ban T; Amgen Asia R&D Center, Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd, Shanghai 201210, China.
  • Li X; Amgen Asia R&D Center, Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd, Shanghai 201210, China.
  • Ma X; Amgen Asia R&D Center, Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd, Shanghai 201210, China.
  • Yang H; Amgen Asia R&D Center, Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd, Shanghai 201210, China.
  • Song Y; Amgen Asia R&D Center, Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd, Shanghai 201210, China.
  • Sun Y; Amgen Asia R&D Center, Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd, Shanghai 201210, China.
  • Shen M; Amgen Research, Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, U.S.A.
  • Li N; Amgen Asia R&D Center, Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd, Shanghai 201210, China.
  • Zhang MY; Amgen Asia R&D Center, Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd, Shanghai 201210, China.
  • Ma Y; Amgen Asia R&D Center, Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd, Shanghai 201210, China.
  • Zhong W; Amgen Asia R&D Center, Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd, Shanghai 201210, China.
  • Zhang M; Amgen Asia R&D Center, Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd, Shanghai 201210, China.
  • Hu LA; Amgen Asia R&D Center, Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd, Shanghai 201210, China liaoyuan@amgen.com.
Biochem J ; 475(23): 3813-3826, 2018 12 06.
Article em En | MEDLINE | ID: mdl-30409826
ABSTRACT
Biased ligands of G protein-coupled receptors (GPCRs) may have improved therapeutic benefits and safety profiles. However, the molecular mechanism of GPCR biased signaling remains largely unknown. Using apelin receptor (APJ) as a model, we systematically investigated the potential effects of amino acid residues around the orthosteric binding site on biased signaling. We discovered that a single residue mutation I109A (I1093.32) in the transmembrane domain 3 (TM3) located in the deep ligand-binding pocket was sufficient to convert a balanced APJ into a G protein signaling biased receptor. APJ I109A mutant receptor retained full capabilities in ligand binding and G protein activation, but was defective in GRK recruitment, ß-arrestin recruitment, and downstream receptor-mediated ERK activation. Based on molecular dynamics simulations, we proposed a molecular mechanism for biased signaling of I109A mutant receptor. We postulate that due to the extra space created by I109A mutation, the phenyl group of the last residue (Phe-13) of apelin rotates down and initiates a cascade of conformational changes in TM3. Phe-13 formed a new cluster of hydrophobic interactions with the sidechains of residues in TM3, including F1103.33 and M1133.36, which stabilizes the mutant receptor in a conformation favoring biased signaling. Interruption of these stabilizing interactions by double mutation F110A/I109A or M113A/I109A largely restored the ß-arrestin-mediated signaling. Taken together, we describe herein the discovery of a biased APJ mutant receptor and provide detailed molecular insights into APJ signaling selectivity, facilitating the discovery of novel therapeutics targeting APJ.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Acoplados a Proteínas G / Domínios Proteicos / Receptores de Apelina / Aminoácidos Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Acoplados a Proteínas G / Domínios Proteicos / Receptores de Apelina / Aminoácidos Idioma: En Ano de publicação: 2018 Tipo de documento: Article